Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

This study has been completed.

Sponsor:

Collaborator:

Southwest Oncology Group

Information provided by (Responsible Party):

National Cancer Institute (NCI)

ClinicalTrials.gov Identifier:

NCT00077428

First received: February 10, 2004

Last updated: January 23, 2013

Last verified: January 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	June 2007 (Final data collection date for primary outcome measure)